Get the Stockscreener App
0.00
100.00%
-115.07
After Hours:
115.11
115.11
+
Arcellx Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
See More
Previous Close:
$115.07
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.73B
Revenue:
$22.29M
Net Income/Loss:
$-228.93M
P/E Ratio:
0.00
EPS:
-4.0547
Net Cash Flow:
$-212.59M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$115.13
Arcellx Inc Stock (ACLX) Company Profile
Name
Arcellx Inc
Sector
Industry
Phone
240-327-0603
Address
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
0.00 | 6.73B | 22.29M | -228.93M | -212.59M | -4.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-22-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-16-25 | Initiated | Stifel | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Redburn Atlantic | Buy |
| Sep-03-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Mar-07-24 | Initiated | Morgan Stanley | Overweight |
| Jan-04-24 | Reiterated | Needham | Buy |
| Dec-19-23 | Initiated | Scotiabank | Sector Outperform |
| Oct-30-23 | Initiated | TD Cowen | Outperform |
| Oct-17-23 | Initiated | UBS | Buy |
| May-18-23 | Initiated | Truist | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
| Mar-14-23 | Initiated | Stifel | Buy |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-13-22 | Resumed | BofA Securities | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-27-22 | Initiated | Needham | Buy |
| Jul-20-22 | Initiated | Canaccord Genuity | Buy |
| Mar-01-22 | Initiated | BofA Securities | Buy |
| Mar-01-22 | Initiated | SVB Leerink | Outperform |
View All
Arcellx Inc Stock (ACLX) Latest News
OpGen Inc. (OPGN) Peer Comparison – Compare with Others - valueresearchonline.com
Arcellx (ACLX) Latest Quarter: The Available Earnings Metric Delivers a Beat in Latest Trading ; Trading Response Is Still PendingBook Value Growth - vinanet.vn
Arcellx (ACLX) Latest Quarter: EPS Exceeds Its Estimate ; Results Are Reported Without a Trading SignalPositive Surprise Momentum - vinanet.vn
7 biopharma M&A deals where layoffs followed - BioSpace
ACLX Q4 2025 Earnings: Narrower-Than-Expected Loss Reflects Clinical-Stage DisciplineProfit Margin Analysis - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineRevenue Guidance Update - vinanet.vn
Gilead Reportedly Eyes Yet Another Acquisition Worth $2B After Arcellx Deal - stocktwits.com
Arcellx (ACLX): Paradigm BioCapital group files 13G/A showing 0% stake - Stock Titan
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss of $1.01 Per Share Underscores Clinical-Stage Focus - vinanet.vn
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Former Arcellx CFO Joins Rani Therapeutics Board After Gilead Acquisition - Stock Titan
Arcellx Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Continued Operational DisciplineBasic EPS Analysis - vinanet.vn
Gilead extends Arcellx tender offer again - MSN
Arcellx (ACLX) Holds Steady as Biotech Stock Consolidates Near SupportSector Sentiment - vinanet.vn
ACLX Q4 2025 Earnings: Narrower-than-Expected Loss Drives Modest Stock GainAnalyst Consensus Shift - vinanet.vn
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer - The National Law Review
Arcellx (ACLX) Stock Analysis: Why Arcellx (ACLX) Is Stuck at $115.07 2026-07-09Dollar Neutral Pair - dars.gov.et
Arcellx Inc. (ACLX) Holds Near Key Support Amidst ConsolidationBuyback Factor - DonanımHaber
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss, Flat Stock ReactionPost-Earnings Reaction - dars.gov.et
Arcellx (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Guidance Update - dars.gov.et
How Arcellx Inc. (ACLX) Affects Rotational Strategy Timing - Stock Traders Daily
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
ACLX Q4 2025 Earnings: Effective Cost Management Leads to Narrower-Than-Expected LossNet Income Trends - dars.gov.et
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-than-Expected Loss on Operational EfficiencyNext Quarter Guidance - dars.gov.et
Arcellx (ACLX) Holds Near $115 as Biotech Stock Consolidates in Narrow RangeDynamic Hedging - DonanımHaber
Arcellx Inc (ACLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcellx Inc (ACLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcellx Inc (ACLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcellx Inc (ACLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arcellx Inc. (ACLX) Holds Near Support as Consolidation ContinuesFast Moving Stocks - newsline.com
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineGuidance Update - newsline.com
Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Arcellx Inc. (ACLX) Consolidates Near Key Support Level as Biotech Sector Awaits CatalystsPrice Gap Fill - newsline.com
Key facts: Gilead completes $7.8B Arcellx buy; closes Ouro Medicines deal - TradingView
Arcellx Inc. (ACLX) Q4 2025 Earnings: Narrower-Than-Expected Loss Signals ProgressWeak Earnings Momentum - dars.gov.et
Arcellx (ACLX) Holds Steady Near $115 as Support and Resistance Levels Define Trading RangegetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx (ACLX) Holds Steady Near Support Amid Biotech Sector VolatilitygetLinesFromResByArray error: size == 0 - lwvtexas.org
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
ARCELLX Q1 2026 Earnings Preview: Recent $ACLX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Arcellx (ACLX) Amendment shows Vestal Point and Wilder report 0% ownership - Stock Titan
[15-12G] Arcellx, Inc. SEC Filing - Stock Titan
Gilead wipes out most of Arcellx workforce - BioSpace
7 months after last layoffs, Bay Area biotech giant does another round - SFGATE
Bay Area biotech takes another hit as Gilead announces major job cuts - Yahoo Finance
Gilead to lay off dozens in Rockville after closing Arcellx acquisition - The Business Journals
Rutgers axes graduation speaker after anti-Israel social media posts allegedly drew student backlash - New York Post
MSN Money - MSN
Gilead to lay off nearly 200 workers after Arcellx acquisition closes - The Business Journals
Bay Area biotech giant Gilead to lay off 108 workers in Redwood City - San Francisco Chronicle
Gilead completes Arcellx buy, securing myeloma treatment anito-cel - Rare Cancer News
Arcellx Inc Stock (ACLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):